Luis E. Altamira-Pena
Bologna, 40126, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
MRI-guided histology of TDP-43 knock-in mice implicates parvalbumin interneuron loss, impaired neurogenesis and aberrant neurodevelopment in amyotrophic lateral sclerosis-frontotemporal dementia.
Journal: Brain communications
Published: February 23, 2021
Deficiency of Mitochondrial Aspartate-Glutamate Carrier 1 Leads to Oligodendrocyte Precursor Cell Proliferation Defects Both In Vitro and In Vivo.
Journal: International journal of molecular sciences
Published: July 30, 2019
A Focused Library of Psychotropic Analogues with Neuroprotective and Neuroregenerative Potential.
Journal: ACS chemical neuroscience
Published: September 26, 2018
Release of soluble and vesicular purine nucleoside phosphorylase from rat astrocytes and microglia induced by pro-inflammatory stimulation with extracellular ATP via P2X7 receptors.
Journal: Neurochemistry international
Published: July 27, 2017
New tacrine dimers with antioxidant linkers as dual drugs: Anti-Alzheimer's and antiproliferative agents.
Journal: European journal of medicinal chemistry
Published: February 10, 2017
Down-regulation of the mitochondrial aspartate-glutamate carrier isoform 1 AGC1 inhibits proliferation and N-acetylaspartate synthesis in Neuro2A cells.
Journal: Biochimica et biophysica acta. Molecular basis of disease
Published: November 10, 2016
Evidence for purine nucleoside phosphorylase (PNP) release from rat C6 glioma cells.
Journal: Journal of neurochemistry
Published: November 09, 2016
Tacrine-resveratrol fused hybrids as multi-target-directed ligands against Alzheimer's disease.
Journal: European journal of medicinal chemistry
Published: October 28, 2016
Multitarget drug design strategy: quinone-tacrine hybrids designed to block amyloid-β aggregation and to exert anticholinesterase and antioxidant effects.
Journal: Journal of medicinal chemistry
Published: September 27, 2014
Histone post-translational modifications in Huntington's and Parkinson's diseases.
Journal: Current pharmaceutical design
Published: January 10, 2013
Showing 1-10 of 10
Last Updated: 09/26/2026